OncoHost's PROphet(R) Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer.
In: Immunotherapy Weekly, 2023-10-17, S. 640-640
serialPeriodical
Zugriff:
Keywords: Biomarkers; Cancer; Chemotherapy; Clinical Research; Clinical Trials and Studies; Cyborgs; Diagnostics and Screening; Drugs and Therapies; Emerging Technologies; Health and Medicine; Lung Cancer; Lung Diseases and Conditions; Lung Neoplasms; Machine Learning; OncoHost; Oncology EN Biomarkers Cancer Chemotherapy Clinical Research Clinical Trials and Studies Cyborgs Diagnostics and Screening Drugs and Therapies Emerging Technologies Health and Medicine Lung Cancer Lung Diseases and Conditions Lung Neoplasms Machine Learning OncoHost Oncology 640 640 1 10/16/23 20231017 NES 231017 2023 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Henlius USA will utilize OncoHost's PROphet(R) platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial (NCT05468489). [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
OncoHost's PROphet(R) Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer.
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2023-10-17, S. 640-640 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|